[Effect of neurotropin (NSP) on allergic reactions (author's transl)].
A study was carried out to examine the effect on neurotropin (NSP) on the 4 types of allergic reactions classified by Coombs and Gell. 1) Type 1: NSP inhibited 48-hr homologous passive cutaneous anaphylaxis (PCA) as well as antigen-induced degranulation of rat mesenterium mast cells. The drug also inhibited both experimental asthma and histamine release from lung tissue in guinea pigs, as mediated by IgE antibody. 2) Type 2: NSP slightly suppressed the increase in urinary protein levels caused by nephrotoxic nephritis in rats and showed a tendency to inhibit Forssman shock in guinea pigs. NSP had an anticomplement activity in vitro but did not inhibit the reversed cutaneous anaphylaxis in rats. 3) Type 3: NSP suppressed an increase in the urinary protein level of rats with glomerulonephritis, as induced by immune complex. 4) Type 4: NSP slightly inhibited the increase in the urinary protein level in glomerulonephritic rats pretreated with IgG. However, the drug did not affect picryl chloride-induced contact dermatitis in mice. We conclude that NSP inhibits allergic reactions used in the present study except for reversed cutaneous anaphylaxis and contact dermatitis, and the most potent activity is seen in the case of Type 1 reaction.
D000818:Animals; D000936:Antigen-Antibody Complex; D001249:Asthma / Q000188:drug therapy; D003877:Dermatitis, Contact / Q000188:drug therapy; D005921:Glomerulonephritis / Q000188:drug therapy / Q000276:immunology; D006168:Guinea Pigs; D006636:Histamine Release / Q000187:drug effects*; D008297:Male; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects*; D011134:Polysaccharides / Q000494:pharmacology* / Q000627:therapeutic use; D011507:Proteinuria; D051381:Rats; D011919:Rats, Inbred Strains; D012771:Shock, Hemorrhagic / Q000188:drug therapy
D000936:Antigen-Antibody Complex; D011134:Polysaccharides; C010491:neurotropin